drugset / Trial / NCT05619783
Extension Study Evaluating The Safety And Tolerability of AMX0035
NaSingle-groupOpen-labelTreatment
Summary
The primary objective is to evaluate the safety and tolerability of AMX0035 over 108 weeks of open label treatment for participants previously enrolled in Study A35-004 (PHOENIX).
Timeline
- Start
- 2022-12-29
- Primary completion
- 2024-10-16
- Completion
- 2024-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sodium Phenylbutyrate | Small molecule | 3 g | Oral |
| Subject | Taurursodiol | Small molecule | 1 g | Oral |